Genome-wide association studies (GWAS) involve scanning the DNA of a large cohort to identify any genetic variants associated with the disease in question. Previous GWAS
EAC
EAC
Genetic Risk Loci, Biomarkers, and Lifestyle Risk Factors in Barrett’s Esophagus and Cancer
Combining CADe and a Mucosal Exposure Device Provides Best Detection During Colonoscopy
In a randomized controlled trial, 1245 participants aged 50 to 75 years were randomized to standard colonoscopy, standard colonoscopy plus an artificial intelligence (AI) detection
Progression in Barrett’s Esophagus Score Can Be Used for Estimating Neoplastic Progression
Barrett’s esophagus (BE) is a known precancerous lesion for esophageal dysplasia and adenocarcinoma (EAC); however, it is unclear who will progress to high-grade dysplasia (HGD)
Artificial Intelligence Similar to Expert Endoscopists at Differentiating Between Mucosal and Submucosal Barrett’s Cancer
Artificial intelligence (AI) systems using convolutional neural networks have been developed to differentiate between esophageal cancer (EAC), high-grade dysplasia, and nondysplastic Barrett’s esophagus. However, until
Upper GI Screening Endoscopy in Individuals With a Family History of Barrett’s Esophagus or Esophageal Cancer
The incidence of esophageal adenocarcinoma (EAC) continues to increase and is still associated with a poor prognosis with a 5-year survival rate of 20%. The
Endoscopic Screening Reduces Mortality From Esophageal Cancer in High-Risk Population
Although esophageal adenocarcinoma (EAC) is the most common type of esophageal cancer in the Western world, esophageal squamous cell carcinoma (ESCC) is the dominant type
Achalasia Patients at Increased Risk for Esophageal Cancer
Achalasia can cause food retention, leading to bacterial overgrowth, irritation, and chronic inflammation, a proposed pathophysiological process that may lead to squamous cell carcinoma (SCC).
Neoplasia Detection Rate in Barrett’s Esophagus: A Measure of High-Quality Upper Endoscopy
Studies have reported that up to 25% of esophageal adenocarcinomas (EACs) are detected within 1 year of index endoscopy (missed cancer), emphasizing the need for